Darrell Nix Email & Phone Number

Colebrook, NH, US

Winchester, Massachusetts, US

Acting VP of R&D working to advance the lead program MMP2/9 inhibitor into clinical studies

Radnor, Pennsylvania, US

Responsible for leading Global early development consulting services Team to engage client companies and connect internal resources to support early stage drug development activities. Typical collaborations include pre-IND meeting support (Briefing Document writing, Meeting Request correspondence, meeting attendance and follow up), IND writing, GLP Tox.

CSO responsible for all nonclinical and early clinical development of novel regenerative therapies in CV space.

Providing consulting services for all size companies in pharmaceutical global drug development. Experienced in all phases of development from discovery candidate selection through commercialization. In addition to helping companies with the drug development process, capable of developing life cycle management and positioning for parnering and acquisition..

Summit, New Jersey, US

Transition role following acquisition of Gloucester Pharmaceuticals.

Responsible for all non-clinical drug development activities to include external relationships with academic institutions and investigator initiated studies. Leading the nonclinical and clinical pharmacology presentation of data in potential partnering discussions. Hold sole ownership of the nonclinical safety, toxicology, ADME, pharmacology and clinical.

Responsible for establishment and operation of Preclinical Drug Development group, including In Vivo Pharmacology, Toxicology, Pharmacokinetics and Drug Metabolism, Clinical Pharmacology, Bioanalytical, Preclinical Documentation and Operations. Grew a functional Development group capable of supporting the IND enabling studies in two therapeutic areas.

Associate Director, Pharmacokinetics and Drug Metabolism Oct 2001-Oct 2004Additional responsibilities included supporting the commercialization of the first in class boronic acid proteasome inhibitor VELCADE™ during pre-launch and launch following US FDA approval by interacting with key opinion leaders in the treatment of patients with multiple myeloma..

Responsible for creation of a DMPK group to support drug development from late stage discovery through early Phase 2 clinical Trials. Responsible for the preparation of documents to support regulatory submissions in Foreign and the US Agencies. Established relationships with several contract research organizations (Quintiles, PPD, MDS, Covance, Advion) for.

Dublin, IE